Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
HIV Immunotherapy
Investigational HIV Therapy Targets Immune Stimulation
March 31st, 2000
Hollis-Eden Pharmaceuticals, Inc., San Diego, California, will make a poster presentation on its promising HIV/AIDS investigational drug therapy, HE2000, at the conference "Novel Biological Approaches to HIV-1 Infection Based on New Insights into HIV Biology." The conference has been scheduled for April 4-10, 2000, in Keystone, Colorado. It will focus on the latest research in HIV structure, the HIV replication cycle, immune response to infection, and the mechanisms involved in disease induction as a backdrop for considering the possibilities for developing innovative therapeutics. Although in recent years major advances have occurred in antiviral...
Source: Drug Week (2000-03-31)
|
